Literature DB >> 22528335

Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population.

Monika Kmetová Sivoňová1, Dušan Dobrota, Róbert Dušenka, Iveta Waczulíková, Peter Slezák, Tatiana Matáková, Silvia Mahmoodová, Dušan Mištuna, Ján Kliment.   

Abstract

Cytochrome P-450c17α (CYP17) and prostate-specific antigen (PSA) genes, which are involved in the androgen metabolism cascade, have been studied as possible candidates for genetic influences on prostate cancer development. Contradictory results prompted us to evaluate the frequencies of polymorphisms in the CYP17 and PSA genes as well as the association between these genetic variants and serum PSA levels in prostate cancer patients and men routinely screened for prostate cancer with PSA in the Slovak male population. The CYP17 and PSA polymorphisms were determined by the PCR-RFLP analysis in 197 Caucasian prostate cancer patients and 256 Caucasian controls. We did not find any association between the CYP17 and PSA genotypes and prostate cancer risk overall, or by grade. Also the total serum PSA levels in the cases with the AG or AA genotype were not significantly higher than in the men with the GG genotype (P > 0.05). Our study did not provide support for the hypothesized relationship between CYP17 and PSA gene polymorphisms and prostate cancer in the Slovak male population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22528335     DOI: 10.1007/s11033-012-1631-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  59 in total

Review 1.  Prostate cancer and race.

Authors:  Otis W Brawley; Ashesh B Jani; Veraj Master
Journal:  Curr Probl Cancer       Date:  2007 May-Jun       Impact factor: 3.187

Review 2.  Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels.

Authors:  Takashi Imamoto; Hiroyoshi Suzuki; Takanobu Utsumi; Takumi Endo; Makoto Takano; Masashi Yano; Koji Kawamura; Naoto Kamiya; Naoki Nihei; Yukio Naya; Tomohiko Ichikawa
Journal:  Future Oncol       Date:  2009-09       Impact factor: 3.404

3.  Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer.

Authors:  Margaret C Binnie; Freda E Alexander; Charlotte Heald; Fouad K Habib
Journal:  Prostate       Date:  2005-06-01       Impact factor: 4.104

4.  The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.

Authors:  N E Allen; M S Forrest; T J Key
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-03       Impact factor: 4.254

5.  A polymorphism in the CYP17 gene is associated with prostate cancer risk.

Authors:  A Gsur; G Bernhofer; S Hinteregger; G Haidinger; G Schatzl; S Madersbacher; M Marberger; C Vutuc; M Micksche
Journal:  Int J Cancer       Date:  2000-08-01       Impact factor: 7.396

6.  PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.

Authors:  John Lai; Mary-Anne Kedda; Kimberly Hinze; Robert L G Smith; John Yaxley; Amanda B Spurdle; C Phillip Morris; Jonathan Harris; Judith A Clements
Journal:  Carcinogenesis       Date:  2006-12-06       Impact factor: 4.944

7.  A polymorphism in the CYP17 gene and risk of prostate cancer.

Authors:  Janet L Stanford; Elizabeth A Noonan; Lori Iwasaki; Suzanne Kolb; Robert B Chadwick; Ziding Feng; Elaine A Ostrander
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-03       Impact factor: 4.254

Review 8.  Lifestyle as risk factor for cancer: Evidence from human studies.

Authors:  Naghma Khan; Farrukh Afaq; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2010-01-18       Impact factor: 8.679

Review 9.  Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.

Authors:  André N Vis; Fritz H Schröder
Journal:  BJU Int       Date:  2009-07-14       Impact factor: 5.588

10.  Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population.

Authors:  R C Sobti; L Gupta; S K Singh; A Seth; P Kaur; H Thakur
Journal:  Cancer Genet Cytogenet       Date:  2008-09
View more
  5 in total

1.  Variation in N-acetyltransferase 2 (NAT2), smoking and risk of prostate cancer in the Slovak population.

Authors:  Marta Vilčková; Jana Jurečeková; Dušan Dobrota; Viera Habalová; Lucia Klimčáková; Iveta Waczulíková; Peter Slezák; Ján Kliment; Monika Kmeťová Sivoňová
Journal:  Med Oncol       Date:  2014-05-11       Impact factor: 3.064

2.  Association of p53 and p21 polymorphisms with prostate cancer.

Authors:  Monika Kmeťová Sivoňová; Marta Vilčková; Ján Kliment; Silvia Mahmood; Jana Jurečeková; Svetlana Dušenková; Iveta Waczulíková; Peter Slezák; Dušan Dobrota
Journal:  Biomed Rep       Date:  2015-07-27

Review 3.  ESR1 Gene Polymorphisms and Prostate Cancer Risk: A HuGE Review and Meta-Analysis.

Authors:  Yu-Mei Wang; Zu-Wang Liu; Jing-Bo Guo; Xiao-Fang Wang; Xin-Xin Zhao; Xuan Zheng
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

4.  Lack of association between NAT2 polymorphism and prostate cancer risk: a meta-analysis and trial sequential analysis.

Authors:  Feng Wang; Zhiqiang Qin; Shuhui Si; Jingyuan Tang; Lingyan Xu; Haoxiang Xu; Ran Li; Peng Han; Haiwei Yang
Journal:  Oncotarget       Date:  2017-07-05

5.  Association of Some Polymorphisms in the VDR Gene, CYP17 Gene and SRD5A2 Gene and Prostate Cancer among Lebanesezzm321990Men

Authors:  Asmahan A El Ezzi; Vladyslav G Boyko; Monika T Baker; Wissam R Zaidan; Kalim M Hraiki; Mohammad A El Saidi; Ruhul H Kuddus
Journal:  Asian Pac J Cancer Prev       Date:  2017-01-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.